Ten Things Doctors Should Know About Celiac

December 5 2014

by Emily Ryan

No Comments

Many physicians, gastroenterologists included, would benefit from a review of this list.
Celiac disease remains under-diagnosed despite being far from rare at 1% of the population.

Celiac Disease: Ten Things That Every Gastroenterologist Should Know

Oxentenko AS, Murray JA.

Clin Gastroenterol Hepatol. 2014 Jul 19.

There are 10 things that all gastroenterologists should know about celiac disease (CD).

(1) The immunoglobulin A tissue transglutaminase is the single best serologic test to use for the detection of CD.

(2) CD can be recognized endoscopically, and water immersion enhances villi detection, although a normal endoscopic appearance does not preclude the diagnosis.

(3) It is recommended that 4 biopsies be taken from the second part of the duodenum and 2 bulb biopsies be taken at the 9 o’clock and 12 o’clock positions to maximize the sensitivity for histologic confirmation of CD.

(4) Consider serologic testing of first-degree relatives, patients with type 1 diabetes mellitus, Down’s, Turner’s, and Williams’ syndromes, as well as those with premature osteoporosis, iron deficiency, abnormal liver biochemistries, and other manifestations of CD.

(5) Patients already on a prolonged gluten-free diet (GFD) should be tested for the presence of HLA DQ2 or DQ8, thereby avoiding the need for further evaluation of CD in non-allelic carriers.

(6) The basic treatment of CD is a strict, lifelong GFD, enabled by an expert dietitian.

(7) Newly diagnosed adults with CD should be assessed for micronutrient deficiencies (iron, B12, folate, zinc, copper), fat soluble vitamin deficiencies (vitamin D), and bone densitometry.

(8) All patients diagnosed with CD should have clinical follow-up to ensure response and adherence to a GFD.

(9) In those with persistent or relapsing symptoms, the robustness of the original diagnosis should be reviewed, gluten exposure sought, and a systematic evaluation for alternative and associated diseases performed.

(10) Evaluate those with refractory disease for malignant transformation.

PMID: 25051511